Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2024 06:45 ET | Source: Pluri Inc.

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract

As part of Pluri’s previously announced $4.2 million 3-year contract with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the option for the second year of the contract has...
May 20, 2024 07:00 ET | Source: Pluri Inc.

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

New production process will be developed based on Pluri’s proprietary 3D cell expansion technologyHuman breast milk oligosaccharides are known to shape the gut microbiota and thus provide health...
May 02, 2024 07:00 ET | Source: Pluri Inc.

Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

Placental Mucosal Associated Invariant T (MAIT) cells are unique unconventional immune T cells which are particularly suitable for the treatment of solid tumors, a significant unmet medical needMAIT...
April 08, 2024 07:00 ET | Source: Pluri Inc.

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Pluri’s patent enables mass-scale production of immune cell therapiesNew patented technology is applicable for the expansion of a variety of immune cellsTechnology sets stage for potential immune cell...
March 28, 2024 07:15 ET | Source: Pluri Inc.

Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

HAIFA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote...
March 27, 2024 07:00 ET | Source: Pluri Inc.

Pluri Inc. Announces 1-for-8 Reverse Share Split

HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), a leading biotechnology company that transforms cells into solutions, today...
March 21, 2024 07:00 ET | Source: Pluri Inc.

Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

International Coffee Organization (ICO) Market Report published on March 7, 2024 highlights alarming price instability challenging the coffee industryAccording to the report, adverse weather...
March 19, 2024 04:00 ET | Source: Pluri Inc.

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote...
March 14, 2024 07:00 ET | Source: Pluri Inc.

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

HAIFA, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today...
March 11, 2024 07:00 ET | Source: Pluri Inc.

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

HAIFA, Israel, March 11, 2024 (GLOBE NEWSWIRE) -- In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company") today...